TrivarX (ASX:TRI) secured firm commitments to raise nearly AU$2.3 million through the placement of 150 million new fully paid ordinary shares at AU$0.015 apiece, according to a Monday filing with the Australian bourse.
The issue price is a nearly 10% discount to the company's 15-day volume-weighted average price.
Participants will be issued one free attaching option for every two new shares subscribed for with an exercise price of AU$0.025 and expiring two and a half years from the date of issue, per the filing.
Proceeds will fund the upcoming clinical trial with the US Department of Veterans Affairs and other ongoing research and development initiatives, the filing stated.
TrivarX's shares climbed nearly 7% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。